Citius Oncology Launches AI Platform to Enhance Commercial Strategy Ahead of LYMPHIR Launch

Citius Oncology, Inc. (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), has deployed a proprietary AI platform to enhance the performance of its commercial team ahead of the anticipated launch of LYMPHIR™, a novel therapy for cutaneous T-cell lymphoma (CTCL). The platform is designed to improve sales and marketing precision by leveraging machine learning to analyze treatment patterns and identify healthcare providers whose patients may benefit from LYMPHIR. The AI system uses company-defined criteria to detect trends in diagnosis and treatment, enabling targeted outreach to prescribers with high-potential patient populations. By continuously learning from real-world U.S. claims data and marketing performance analytics, the platform refines its predictive capabilities over time, supporting dynamic content delivery and personalized engagement across digital and in-person touchpoints. Leonard Mazur, Chairman and CEO of both Citius Oncology and Citius Pharma, emphasized the strategic value of the platform: "We look forward to having this innovative AI platform amplify the precision and impact of our experienced commercial and marketing teams. This proprietary system is designed to augment clinical expertise and experience, allowing us to connect science, clinical need, and patient access in a more intelligent and scalable way." LYMPHIR (denileukin diftitox-cxdl) received FDA approval in August 2024 for adult patients with relapsed or refractory Stage I-III CTCL after at least one prior systemic therapy. It is a targeted immune therapy that binds to IL-2 receptors on cancer cells and regulatory T-cells, delivering a cytotoxic payload that induces cell death and transiently depletes immunosuppressive T-regs to enhance anti-tumor activity. The platform supports Citius Oncology’s lean commercial infrastructure by enabling faster, data-driven decisions, accelerating provider education, and improving patient access to care. With an estimated initial market exceeding $400 million and limited curative options for advanced CTCL, LYMPHIR addresses a significant unmet medical need. The company highlighted that the AI tool is part of a broader strategy to integrate advanced technology into commercial operations, ensuring efficient and effective market entry. The platform’s continuous learning model allows it to adapt to emerging treatment behaviors and utilization trends, maintaining relevance and impact as the market evolves. Citius Oncology also noted the importance of safety in its commercial approach. LYMPHIR carries a boxed warning for capillary leak syndrome, along with warnings for visual impairment, infusion-related reactions, hepatotoxicity, and embryo-fetal toxicity. The company is committed to providing comprehensive education and monitoring tools to support safe and effective use. For more information, visit www.citiusonc.com.